Log In
Print this Print this

CAR T cell therapy targeting CD33

  Manage Alerts
Collapse Summary General Information
Company Ziopharm Oncology Inc.
DescriptionChimeric antigen receptor (CAR)-modified T cells targeting CD33
Molecular Target CD33
Mechanism of Action 
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPreclinical
Standard IndicationAcute myelogenous leukemia (AML)
Indication DetailsTreat acute myelogenous leukemia (AML); Treat relapsed or refractory acute myeloid leukemia (AML)
Regulatory Designation
PartnerIntrexon Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today